SCHEMBL669263

SCHEMBL669263

COC(=O)c1ccc(C)c(S(=O)(=O)Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
CYP2C9 P11712 6/20 0.50
TSHR P16473 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C19 P33261 1/20 0.50
RAB9A P51151 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
XDH P47989 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
NOTUM Q6P988 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31587402 1.00 ALDH1A1 (0.50) ALDH1A1CYP2C9TSHRSMN1; SMN2L3MBTL1
SCHEMBL6970979 0.87 VCAM1 (0.49) ALDH1A1CYP2C9TSHRSMN1; SMN2L3MBTL1
SCHEMBL28614221 0.87 SMN1; SMN2 (0.40) ALDH1A1CYP2C9TSHRSMN1; SMN2L3MBTL1
SCHEMBL1495428 0.85 VCAM1 (0.57) ALDH1A1CYP2C9TSHRSMN1; SMN2L3MBTL1
SCHEMBL30031799 0.85 VCAM1 (0.57) ALDH1A1CYP2C9TSHRSMN1; SMN2L3MBTL1
SCHEMBL9324149 0.83 KDM4E (0.53) ALDH1A1TSHRSMN1; SMN2L3MBTL1CYP1A2
SCHEMBL13545951 0.83 CA1 (0.53) ALDH1A1CYP2C9TSHRL3MBTL1RAB9A
SCHEMBL6152074 0.83 KDM4E (0.56) ALDH1A1TSHRSMN1; SMN2L3MBTL1CYP1A2
SCHEMBL1495720 0.83 ALDH1A1 (0.65) ALDH1A1CYP2C9TSHRSMN1; SMN2L3MBTL1
SCHEMBL19518885 0.82 RAD52 (0.39) ALDH1A1SMN1; SMN2L3MBTL1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
CN-117229257-A Meta-sulfamoyl benzamide compound and preparation method, pharmaceutical composition and application thereof 中国药科大学 2023-12-15 CN disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
EP-3883650-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2021-09-29 EP disclosed
CN-113056305-A Compound (I) 格雷沃尔夫治疗有限公司 2021-06-29 CN disclosed
US-9617208-B2 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-04-11 US disclosed
US-20150336880-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS THE JOHNS HOPKINS UNIVERSITY 2015-11-26 US disclosed
US-9115064-B2 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors THE JOHNS HOPKINS UNIVERSITY (US) 2015-08-25 US disclosed
WO-2015004212-A1 INHIBITOR OF NEUROPILIN AND USE THEREOF FOR THE TREATMENT OF NEUROPILIN-RELATED DISEASES TRAGEX PHARMA (FR) 2015-01-15 WO disclosed
WO-2015004212-A1 INHIBITOR OF NEUROPILIN AND USE THEREOF FOR THE TREATMENT OF NEUROPILIN-RELATED DISEASES TRAGEX PHARMA (FR) 2015-01-15 WO disclosed
WO-2010094695-A1 PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-26 WO disclosed
WO-2010094695-A1 PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-26 WO disclosed
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 EP disclosed
US-20090163487-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS THE JOHNS HOPKINS UNIVERSITY 2009-06-25 US disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO disclosed
EP-1277754-B1 IMIDAZOPYRIDINE DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2005-07-27 EP disclosed
US-6653320-B2 Imidazopyridine derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-11-25 US disclosed
EP-1277754-A1 IMIDAZOPYRIDINE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-01-22 EP disclosed
US-20020151549-A1 Such as 3-(6-bromo-2-methylimidazo(1,2-a)pyridin-3-yl)-1H-pyrazol-1-yl 2-methyl-5-nitrophenyl sulfone; useful as phosphatidylinositol-3-kinase (PI3K) inhibitors and antitumor agents ASTELLAS PHARMA INC. (JP) 2002-10-17 US disclosed
US-6403588-B1 PHOSPHATIDYLINOSITOL 3 KINASE (PI3K) INHIBITING ACTIVITY WHICH ARE USEFUL AS MEDICAMENTS, MORE PARTICULARLY AS ANTITUMOR AGENT YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151549-A1 Such as 3-(6-bromo-2-methylimidazo(1,2-a)pyridin-3-yl)-1H-pyrazol-1-yl 2-methyl-5-nitrophenyl sulfone; useful as phosphatidylinositol-3-kinase (PI3K) inhibitors and antitumor agents MTMR1, PIK3CA, PIK3CD ALDH1A1 2851/4885CYP2C9 4112/4885TSHR 3904/4885
US-20090163487-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS TNNI3, TNNC1, NME4 ALDH1A1 2441/4885CYP2C9 895/4885TSHR 2239/4885
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 ALDH1A1 2613/4885CYP2C9 82/4885TSHR 124/4885
US-20150336880-A1 N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS TNNI3, TNNC1, NME4 ALDH1A1 2441/4885CYP2C9 895/4885TSHR 2239/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR ALDH1A1 276/4885CYP2C9 708/4885TSHR 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.